1. |
O’Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path [J]. Shock, 1999; 12(6)∶ 411.
|
2. |
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine [J]. Chest, 1992; 101(6)∶ 1644.
|
3. |
Gould IM, MacKenzie FM. The response of Enterobacteriaceae to betalactam antibiotics“round forms, filaments and the root of all evil” [J]. J Antimicrob Chemother, 1997; 40(4)∶ 495.
|
4. |
Sprung CL, Eidelman LA, Pizov R, et al. Influence of alterations in foregoing lifesustaining treatment practices on a clinical sepsis trial. The HA1A Sepsis Study Group [J]. Crit Care Med, 1997; 25(3)∶ 383.
|
5. |
Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group [J]. Crit Care Med, 1995; 23(6)∶ 994.
|
6. |
Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution [J]. Science, 1997; 276(5320)∶ 1861.
|
7. |
Axtelle T, Pribble J. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis [J]. J Endotoxin Res, 2001; 7(4)∶ 310.
|
8. |
Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome [J]. Ann Intern Med, 1993; 119(8)∶ 771.
|
9. |
Hassouna H, Quinn C. Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC) [J]. Biophys Chem, 2002; 95(2)∶ 109.
|
10. |
Ebihara I, Nakamura T, Shimada N, et al. Effect of hemoperfusion with polymyxin Bimmobilized fiber on plasma endothelin1 and endothelin1 mRNA in monocytes from patients with sepsis [J]. Am J Kidney Dis, 1998; 32(6)∶ 953.
|
11. |
Mitteregger R, White A, Weber C, et al. In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment [J]. Ther Apher, 1999; 3(3)∶ 257.
|